HK Stock Market Move | PEGBIO CO-B (02565) opened more than 11% higher; core product Paidakang successfully included in the 2026 national medical insurance catalog.

date
09:23 16/11/2026
avatar
GMT Eight
PEGBIO CO-B (02565) opened more than 11% higher. As of press time, it was up 11.54% at HK$3.625, with a turnover of HK$1.9996 million.
PEGBIO CO-B (02565) opened more than 11% higher. As of press time, it was up 11.54% at HK$3.625, with a turnover of HK$1.9996 million. On the news front, PEGBIO announced that its core self-developed innovative drug product, beinaglutide injection (trade name: Paidakang), has been successfully included in the latest "2026 National Drug Catalog for Basic Medical Insurance, Maternity Insurance, and Work-Related Injury Insurance" published by the National Healthcare Security Administration. Public information shows that Paidakang is a once-weekly GLP-1 formulation for blood glucose control in adults with type 2 diabetes. Previously, PEGBIO entered into an exclusive commercialization partnership in mainland China with Shanghai Tengrui Pharmaceutical, setting a target of cumulative sales exceeding RMB10 billion, with product sales revenue recognized by PEGBIO. This medical insurance inclusion, combined with the partner's nationwide promotion network, is expected to accelerate the ramp-up of Paidakang and provide key support for the aforementioned commercialization target.